MGC Pharmaceuticals Limited (MXC.AX)
| Previous close | 0.0070 |
| Open | 0.0090 |
| Bid | 0.0130 x 125665700 |
| Ask | 0.0140 x 8008500 |
| Day's range | 0.0090 - 0.0130 |
| 52-week range | 0.0070 - 0.0280 |
| Volume | |
| Avg. volume | 1,400,314 |
| Market cap | 37.264M |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 28 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.04 |
- Simply Wall St.
MGC Pharmaceuticals First Half 2023 Earnings: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)
MGC Pharmaceuticals ( ASX:MXC ) First Half 2023 Results Key Financial Results Revenue: AU$2.66m (up 3.8% from 1H 2022...
- PR Newswire
MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Long COVID patients with a new herbal inspired medicine.
- PR Newswire
MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK
MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.
